Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Scientists to create new human monoclonal antibody targeting protein associated with cancer

Researchers have discovered a unique monoclonal antibody that can effectively reach inside a cancer cell, a key goal for these important anticancer agents, since most proteins that cause cancer or are associated with cancer are buried inside cancer cells.

14 Mar 2013

Immune system B cells play crucial role in defence of pathogens

Immune system B cells play a crucial role in the defence of pathogens; when they detect such an intruder, they produce antibodies that help to combat the enemy.

13 Mar 2013

Researchers determine way to predict and protect against new strains of flu virus

Researchers have determined a way to predict and protect against new strains of the flu virus, in the hope of improving immunity against the disease.

13 Mar 2013

Studies show protein semaphorin 3A helps detect acute kidney injury

A guidance cue that helps kidneys form may also be a red flag that they are in danger, researchers report.

13 Mar 2013

New, inexpensive nano-biosensor can detect Listeria monocytogenes in food

The foodborne bacteria Listeria monocytogenes sickens about 2,500 people in the U.S. each year and many more worldwide, killing about 25-30% of those infected. Listeriosis is caused by eating food contaminated with L. monocytogenes, and current methods for detecting the bacteria are costly and time consuming.

13 Mar 2013

Anti-cancer drug conjugates: an interview with Dr Andreas Menrad, CSO Ablynx and Dr Chris Martin, CEO Spirogen

Antibodies and in the case of Ablynx, Nanobodies, can be raised and selected to bind with high affinity selectively to cancer cells in a tumour. Cancer cells are exquisitely sensitive to certain toxins such as the PBDs produced by Spirogen.

12 Mar 2013

Influenza drug: an interview with Dr Jenny McKimm-Breschkin, CSIRO

Influenza or flu for short is caused by a family of viruses, which can be called influenza A or influenza B. Influenza A viruses are found in humans, animals – like swine and horses- and mostly aquatic birds. Influenza B is only found in humans.

11 Mar 2013

Inclacumab reduces damage to heart muscle during angioplasty

A single dose of an investigational anti-inflammatory drug called inclacumab considerably reduces damage to heart muscle during angioplasty (the opening of a blocked artery), according to a recent international clinical trial spearheaded by Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, affiliated with the University of Montreal.

11 Mar 2013

Investigational treatment for ulcerative colitis (UC) and Crohn’s disease (CD) has Marketing Authorisation Application submitted

Takeda Pharmaceutical Company Limited (“Takeda”) today announced that a Marketing Authorisation Application (MAA) has been submitted to The European Medicines Agency (EMA) for vedolizumab, an investigational, gut-selective humanized monoclonal antibody for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD), the two most common types of inflammatory bowel disease (IBD).

8 Mar 2013

ADMA Biologics initiates enrollment in RI-002 Phase III study for PIDD

ADMA Biologics, Inc. (ADMA), a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases, announced that the first patient enrolled in the pivotal Phase III clinical study of its RI-002 has been dosed.

7 Mar 2013

Omalizumab scratches the itch for urticaria patients

The monoclonal antibody omalizumab seems to be effective at relieving symptoms for patients with chronic idiopathic urticaria who have not responded to H1-antihistamine therapy, report US researchers.

5 Mar 2013

HIV might promote aging and disease progression in people with HCV, study results suggest

Infectious disease experts at Johns Hopkins have found that among people infected with the hepatitis C virus, co-infection with HIV, speeds damage and scarring of liver tissue by almost a decade.

5 Mar 2013

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

Sanofi and Regeneron Pharmaceuticals, Inc. announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting of the American Academy of Dermatology (AAD) in Miami.

4 Mar 2013

Melanoma tumours deliberately create conditions that knock out body's premier immune defence

New research in the Journal of Clinical Investigation reveals that tumours in melanoma patients deliberately create conditions that knock out the body's 'premier' immune defence and instead attract a weaker immune response unable to kill off the tumour's cancerous cells.

2 Mar 2013

Synthetic progesterone birth control injections have vulnerability to certain infections: Research

Women who are pregnant or using synthetic progesterone birth control injections have a conspicuous vulnerability to certain infections including malaria, Listeria, HIV, and herpes simplex virus.

2 Mar 2013

Anti-LG3 associated with high rate of organ rejection during transplantation

A team led by Dr. Marie-Jos-e H-bert from the University of Montreal Hospital* Research Centre (CRCHUM) has discovered a new cause of organ rejection in some kidney transplant patients. Her team has identified a new class of antibodies - anti-LG3 - which when activated lead to severe rejection episodes associated with a high rate of organ loss.

28 Feb 2013

Engineering chemotherapy drugs' shape increases their ability to target and inhibit cancer cells

Bioengineering researchers at University of California, Santa Barbara have found that changing the shape of chemotherapy drug nanoparticles from spherical to rod-shaped made them up to 10,000 times more effective at specifically targeting and delivering anti-cancer drugs to breast cancer cells.

28 Feb 2013

EpiCept fourth quarter revenue decreases to $0.1 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2012, and provided an update on the Company's merger with Immune Pharmaceuticals, Ltd. (Immune).

28 Feb 2013

Study designs and tests 60 compounds for their ability to kill human cancer cells

Inspired by a chemical that fungi secrete to defend their territory, MIT chemists have synthesized and tested several dozen compounds that may hold promise as potential cancer drugs.

28 Feb 2013

Taiho Pharmaceutical seeks Japanese approval for TAS-102 to treat colorectal cancer

Taiho Pharmaceutical Co., Ltd. announced on February 27 that it submitted an application on February 26 for approval of the manufacture and marketing of the novel oral nucleoside antitumor agent TAS-102 (combination of trifluorothymidine (FTD) and tipiracil hydrochloride (TPI)) to the Japanese Ministry of Health, Labor and Welfare.

27 Feb 2013

Antibody News and Research

Further Reading

Scientists to create new human monoclonal antibody targeting protein associated with cancer

Immune system B cells play crucial role in defence of pathogens

Researchers determine way to predict and protect against new strains of flu virus

Studies show protein semaphorin 3A helps detect acute kidney injury

New, inexpensive nano-biosensor can detect Listeria monocytogenes in food

Anti-cancer drug conjugates: an interview with Dr Andreas Menrad, CSO Ablynx and Dr Chris Martin, CEO Spirogen

Influenza drug: an interview with Dr Jenny McKimm-Breschkin, CSIRO

Inclacumab reduces damage to heart muscle during angioplasty

Investigational treatment for ulcerative colitis (UC) and Crohn’s disease (CD) has Marketing Authorisation Application submitted

ADMA Biologics initiates enrollment in RI-002 Phase III study for PIDD

Omalizumab scratches the itch for urticaria patients

HIV might promote aging and disease progression in people with HCV, study results suggest

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

Melanoma tumours deliberately create conditions that knock out body's premier immune defence

Synthetic progesterone birth control injections have vulnerability to certain infections: Research

Anti-LG3 associated with high rate of organ rejection during transplantation

Engineering chemotherapy drugs' shape increases their ability to target and inhibit cancer cells

EpiCept fourth quarter revenue decreases to $0.1 million

Study designs and tests 60 compounds for their ability to kill human cancer cells

Taiho Pharmaceutical seeks Japanese approval for TAS-102 to treat colorectal cancer

Antibodies eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News